BRPI0507345A - composto antitrombótico - Google Patents

composto antitrombótico

Info

Publication number
BRPI0507345A
BRPI0507345A BRPI0507345-6A BRPI0507345A BRPI0507345A BR PI0507345 A BRPI0507345 A BR PI0507345A BR PI0507345 A BRPI0507345 A BR PI0507345A BR PI0507345 A BRPI0507345 A BR PI0507345A
Authority
BR
Brazil
Prior art keywords
oligosaccharide
residue
spacer
compounds
iiia antagonist
Prior art date
Application number
BRPI0507345-6A
Other languages
English (en)
Inventor
Rogier Christian Buijsman
Martin De Kort
Dirk Gerrit Meuleman
Constant Van Boeckel
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34814249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507345(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0507345A publication Critical patent/BRPI0507345A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/08—Polyoxyalkylene derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSTO ANTITROMBóTICO". A presente invenção refere-se a compostos da fórmula (A) oligossacarídeo-espaçador-antagonista de Gpllb/llla (A), em que o oligossacarídeo é um resíduo de oligossacarídeo negativamente carregado contendo quatro a vinte e cinco unidades de monossacarídeos com a carga compensada por contra-íons positivamente carregados, e em que o resíduo de oligossacarídeo é derivado de um oligossacarídeo que tem por si só atividade anti-Xa (mediada por AT-III); o espaçador é uma ligação ou um resíduo ligante essencialmente farmacologicamente inativo; o antagonista de GPIIb/IIIa é um resíduo que imita o fragmento RGD e/ou K(QA)GD de fibrinogênio, contendo tipicamente uma porção opcionalmente esterificada carboxilato e uma porção básica localizadas no resíduo em uma distância de 1 a 2 nm uma da outra; ou um sal farmaceuticamente aceitável, um pro-fármaco ou um solvato do mesmo. Os compostos da invenção possuem atividade antitrombótica e podem ser usados no tratamento ou prevenção de doenças trombóticas.
BRPI0507345-6A 2004-03-05 2005-03-03 composto antitrombótico BRPI0507345A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04005343A EP1574516A1 (en) 2004-03-05 2004-03-05 Antithrombotic compound
PCT/EP2005/002881 WO2005090382A1 (en) 2004-03-05 2005-03-03 Antithrombotic compound

Publications (1)

Publication Number Publication Date
BRPI0507345A true BRPI0507345A (pt) 2007-07-03

Family

ID=34814249

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507345-6A BRPI0507345A (pt) 2004-03-05 2005-03-03 composto antitrombótico

Country Status (11)

Country Link
US (1) US7576071B2 (pt)
EP (2) EP1574516A1 (pt)
JP (1) JP4705093B2 (pt)
KR (1) KR101127254B1 (pt)
CN (1) CN1930182B (pt)
AU (1) AU2005223339B2 (pt)
BR (1) BRPI0507345A (pt)
CA (1) CA2555036C (pt)
HK (1) HK1101881A1 (pt)
IL (1) IL177296A (pt)
WO (1) WO2005090382A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
EP1609784A1 (de) * 2004-06-25 2005-12-28 Boehringer Ingelheim Pharma GmbH & Co.KG Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen
EP1991272A2 (en) * 2005-10-10 2008-11-19 N.V. Organon Antithrombotic compound
RU2434876C2 (ru) * 2005-10-10 2011-11-27 Н.В. Органон Антитромботические двойные ингибиторы, включающие биотиновую метку
US8183228B2 (en) * 2005-10-10 2012-05-22 MSD OSS B.V. Netherlands Anticoagulant antithrombotic dual inhibitors comprising a biotin label
WO2010065717A1 (en) 2008-12-05 2010-06-10 Mochida Pharmaceutical Co., Ltd. Morpholinone compounds as factor ixa inhibitors
US9566297B2 (en) 2009-02-17 2017-02-14 Novelmed Therapeutics, Inc. Methods and compositions for inhibiting cellular proliferation and surgical adhesion
CN103917552B (zh) * 2011-06-17 2017-03-29 卡博梅麦特斯公司 具有短半衰期和高活性的合成五糖

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5960394A (en) * 1993-01-04 1994-08-15 Regents Of The University Of California, The Platelet-specific therapeutic compound and method of treating platelet-mobilizing diseases
NZ264340A (en) 1993-09-01 1995-04-27 Akzo Nobel Nv Bisconjugate comprising two saccharides and a spacer, use in pharmaceutical compositions
FR2749849B1 (fr) * 1996-06-14 1998-09-04 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2751334B1 (fr) * 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
CA2318215A1 (en) * 1998-02-02 1999-08-05 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a gp iib/iiia antagonist
US6486129B1 (en) * 1998-06-17 2002-11-26 Akzo Nobel N.V. Antithrombotic compounds
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
TWI289566B (en) * 1999-12-07 2007-11-11 N.V.Organon Antithrombotic compound
US20030199457A1 (en) 2002-04-17 2003-10-23 El-Naggar Mawaheb M. Prevention and treatment of thromboembolic disorders associated with arterial & venous thrombosis

Also Published As

Publication number Publication date
EP1574516A1 (en) 2005-09-14
WO2005090382A1 (en) 2005-09-29
JP4705093B2 (ja) 2011-06-22
IL177296A (en) 2011-03-31
KR101127254B1 (ko) 2012-06-14
US7576071B2 (en) 2009-08-18
CN1930182A (zh) 2007-03-14
AU2005223339B2 (en) 2011-06-23
AU2005223339A1 (en) 2005-09-29
JP2008500960A (ja) 2008-01-17
CN1930182B (zh) 2011-11-16
IL177296A0 (en) 2006-12-10
US20070293442A1 (en) 2007-12-20
CA2555036A1 (en) 2005-09-29
CA2555036C (en) 2013-04-16
EP1725577A1 (en) 2006-11-29
HK1101881A1 (en) 2007-10-26
KR20060125888A (ko) 2006-12-06

Similar Documents

Publication Publication Date Title
BRPI0507345A (pt) composto antitrombótico
BRPI0508461A (pt) diaminopirimidinas como antagonistas de p2x3 e p2x2/3
BRPI0507544A (pt) combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias
BRPI0517945A (pt) derivados de quinuclidina e seu uso como antagonistas de receptor muscarìnico m3
BRPI0511327A (pt) combinações de glicopirrolato e agonistas do adrenorreceptor beta2
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
BRPI0518231A2 (pt) derivados de 2-amido-4-feniltiazol, o respectivo preparo e a respectiva aplicaÇço em terapÊutica
BRPI0514536A (pt) uso de oligossacarìdeos não-digerìveis e sacarìdeo de galactose digerìvel, e, composição adequada para o tratamento e/ou prevenção de infecções do trato respiratório e/ou doença de infecção do trato respiratório
BRPI0514357A (pt) combinações para o tratamento de doenças que envolvem a proliferação de células
BRPI0606817A2 (pt) derivados de piridazina e seu uso como agentes terapêuticos
BRPI0509245A (pt) cloridrato [4-(5-aminoetil-2-flúor-fenil)-piperidina-1-il](4-bromo-3 -metil-5-propóxi-tiofeno-2-il)-metanona como um inibidor de triptase de mastócito
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
WO2007042470A3 (en) Antithrombotic compound
JP2002504110A (ja) Ｘａ因子の直接または間接的選択阻害剤の、単独および／または抗血小板凝集活性を有する化合物と組み合わせた動脈血栓塞栓症における治療および予防への組成および使用
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
SK14732003A3 (sk) Farmaceutická kompozícia obsahujúca antagonistu receptora P2T a ďalšie antitrombotické činidlo a jej použitie pri liečení trombózy
AR078082A1 (es) Composiciones farmaceuticas que comprenden fucanos modificados, metodos y kits relacionados
NO20081619L (no) Antitrombotiske dobbel inhibitorer omfattende en biotin markør
BR0309028A (pt) Compostos policìclicos como antagonistas potentes de alfa2-adrenoceptores
BR0313384A (pt) Derivados de cromona como inibidores de metaloproteinases de matriz
BRPI0418973A (pt) composições de risedronato e seus métodos de uso
RS51858B (en) 4 - [(3-FLUOROPHENOXY) PHENYLMETHYL] PIPERIDINE METANSULPHONATE: ITS USES, PROCESSING METHODS AND PHARMACEUTICAL COMPOSITIONS
ES2300877T3 (es) Derivados de esteroides glucosilados con actividad antimigratoria.
BR0315462A (pt) Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação
BRPI0518560A2 (pt) composto antitrombàtico, composiÇço farmacÊutica, processo para a preparaÇço do composto e uso do composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]